<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5619">
  <stage>Registered</stage>
  <submitdate>3/05/2012</submitdate>
  <approvaldate>3/05/2012</approvaldate>
  <nctid>NCT01592747</nctid>
  <trial_identification>
    <studytitle>Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine</studytitle>
    <scientifictitle>A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of the Safety and Efficacy of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated With Memantine</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>MEM-MD-68</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Autism Spectrum Disorder (ASD)</healthcondition>
    <healthcondition>Autism</healthcondition>
    <healthcondition>Autistic Disorder</healthcondition>
    <healthcondition>Asperger's Disorder</healthcondition>
    <healthcondition>Asperger's</healthcondition>
    <healthcondition>Pediatric Autism</healthcondition>
    <healthcondition>Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)</healthcondition>
    <healthcondition>Pervasive Child Development Disorder</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Autistic spectrum disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Other mental health disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Memantine Hydrochloride (HCl)
Treatment: drugs - Memantine Hydrochloride (HCl)
Treatment: drugs - Placebo capsules

Experimental: Memantine 1 - Patients randomized to the full dose arm will continue taking memantine at the same tolerability and weight based dose achieved in lead-in Study MEM-MD-91

Experimental: Memantine 2 - Patients randomized to the reduced dose arm will take memantine at the tolerability and weight based dose that they received in lead in Study MEM-MD-91 reduced by at least 50%.

Placebo Comparator: Placebo - Patients randomized to the placebo.


Treatment: drugs: Memantine Hydrochloride (HCl)
Patients randomized to the full dose arm will continue taking memantine at the same tolerability and weight based dose achieved in lead-in Study MEM-MD-91. Dosing will be once daily for 12 weeks.

Treatment: drugs: Memantine Hydrochloride (HCl)
Patients randomized to the reduced dose arm will take memantine at the tolerability and weight based dose that they received in lead in Study MEM-MD-91 reduced by at least 50%. Dosing will be once daily for 12 weeks.

Treatment: drugs: Placebo capsules
Patients randomized to the placebo will be dosed once daily for 12 weeks.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The primary outcome measure in this study will be the proportion of patients meeting the criterion for Loss of Therapeutic Response (LTR) by the end of the study. - The primary outcome measure in this study will be the proportion of patients meeting the criterion for Loss of Therapeutic Response (LTR) by the end of the study (Visit 7/Week 12).</outcome>
      <timepoint>Baseline to week 12</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Children's Communication Checklist-2 (CCC-2)</outcome>
      <timepoint>Baseline to week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to the first visit when a patient shows LTR following randomization to memantine or placebo (time to the first LTR)</outcome>
      <timepoint>Baseline to week 12</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Completed at least 12 weeks of exposure to study drug in lead-in study MEM-MD-91

          2. Met responder criterion at two consecutive visits separated by at least two weeks in
             lead-in study MEM-MD-91

          3. Provide written informed assent, when developmentally appropriate, to participate in
             the study before conduct of any study-specific procedures. The parent/guardian/LAR
             must provide written informed consent before the patient's participation in the study.
             A separate written informed consent for the caregiver must also be obtained before the
             conduct of any study specific procedures

          4. Have a knowledgeable caregiver who is capable of providing reliable information about
             the patient's condition, attending all clinic visits with the patient, and overseeing
             the administration of study drug. Every effort should be made to maintain the same
             caregiver as used in the lead-in study throughout this study

          5. Have normal results from the physical examination, laboratory tests, ECG, and vital
             signs at Visit 1 of this study (last visit of Study MEM-MD-91). Any abnormal findings
             must be deemed not clinically significant by the Investigator and documented

          6. Be able to speak and understand English sufficiently (or their native language if this
             can be accommodated by the site), as well as have a caregiver and parent/guardian/LAR
             who is able to speak and understand English sufficiently (or their native language if
             this can be accommodated by the site), to comprehend the nature of the study and to
             allow for the completion of all study assessments

          7. Have a family that is sufficiently organized and stable to guarantee adequate safety
             monitoring and continuous attendance to clinic visits for the duration of the study

          8. Females who are 9 years and older or who have had onset of menses must have a negative
             urine pregnancy test at Visit 1</inclusivecriteria>
    <inclusiveminage>6</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>12</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Patients with a concurrent medical condition that might interfere with the conduct of
             the study, confound interpretation of the study results, or endanger the patient's
             well being

          2. Significant risk of suicidality

          3. Patients with evidence or history of malignancy (other than excised basal cell
             carcinoma) or any significant hematologic, endocrine, cardiovascular (including any
             rhythm disorder), neurologic, respiratory, renal, hepatic, or gastrointestinal disease

          4. Female patients of child-bearing potential who are not using or not willing to use a
             conventional method of contraception approved by the PI. Abstinence is an acceptable
             method of contraception

          5. Patients requiring treatment with prohibited concomitant medications

          6. Patients who, in the opinion of the Investigator, might not be suitable for the study

          7. Employee or immediate relative of an employee of Forest Laboratories, Inc., any of its
             affiliates or partners, or the study center</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>480</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/10/2013</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arkansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nebraska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nevada</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Mexico</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Dakota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Dakota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>West Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brussel</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bruxelles</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Hoboken</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Colombia</country>
      <state>Barranquilla</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Colombia</country>
      <state>Bello</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Estonia</country>
      <state>Tallinn</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bron Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Gyula</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Iceland</country>
      <state>Kopavogur</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Roma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Siena</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Gyeongsangnam-do</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Wellington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Gdansk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Kielce</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Kobierzyce</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Serbia</country>
      <state>Belgrade</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Serbia</country>
      <state>Nis</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Serbia</country>
      <state>Novi Sad</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Western Cape</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>MÃ¡laga</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Donetsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Kharkiv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Kherson,Vil. Stepanivka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Kyiv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Odesa</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Forest Laboratories</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This clinical study will be a 12-week, multicenter, double-blind, placebo-controlled,
      randomized withdrawal study in pediatric outpatients with autism, Asperger's Disorder, or
      Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS). The objective is to
      evaluate the safety, tolerability, and efficacy of memantine therapy compared with placebo.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01592747</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Jordan Lateiner, MS, MBA</name>
      <address>Forest Research Institute, Inc.- A Subsidiary of Forest Laboratories, Inc.</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>